624729-74-4Relevant articles and documents
Tetrahydro-naphthols as orally available TRPV1 inhibitors
Urbahns, Klaus,Yura, Takeshi,Gupta, Jang B.,Tajimi, Masaomi,Fujishima, Hiroshi,Masuda, Tsutomu,Yamamoto, Noriyuki,Ikegami, Yuka,Marumo, Makiko,Yasoshima, Kayo,Yoshida, Nagahiro,Moriwaki, Toshiya,Madge, David,Chan, Fiona,Mogi, Muneto
scheme or table, p. 3408 - 3411 (2012/06/29)
Starting from a naphthol-based lead series with low oral bioavailability, we have identified potent TRPV1 antagonists with oral bioavailability in rats. These compounds emerged from SAR studies aimed at replacing the lead's phenol structure whilst maintai
Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
-
Page 11, (2008/06/13)
The invention relates to the application of Vanilloid receptor (VR) 1 inhibitors for drug development and for the treatment of HIV-mediated neuropathies and neuropathic pain states. Further, the inventor identified a novel signaling cascade connecting the
HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES
-
Page 41-42, (2008/06/13)
This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excelle